Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in Humacyte, Inc. (NASDAQ:HUMA) by 4.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,135,133 shares of the company’s stock after acquiring an additional 94,915 shares during the quarter. Geode Capital Management LLC owned approximately 1.70% of Humacyte worth $10,785,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vontobel Holding Ltd. purchased a new position in Humacyte in the 4th quarter worth about $50,000. Brookstone Capital Management purchased a new position in shares of Humacyte in the fourth quarter worth approximately $56,000. ACT Wealth Management LLC acquired a new stake in shares of Humacyte during the fourth quarter valued at approximately $57,000. HighTower Advisors LLC acquired a new stake in shares of Humacyte during the fourth quarter valued at approximately $66,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Humacyte in the 4th quarter valued at approximately $99,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Kathleen Sebelius bought 50,000 shares of the firm’s stock in a transaction on Tuesday, April 8th. The stock was purchased at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares of the company’s stock, valued at $120,393.24. This trade represents a 121.34 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Dale A. Sander purchased 20,000 shares of the stock in a transaction on Thursday, April 10th. The shares were bought at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares of the company’s stock, valued at approximately $62,118. The trade was a 97.09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 83,993 shares of company stock valued at $118,224 over the last ninety days. Corporate insiders own 11.20% of the company’s stock.

Humacyte Trading Down 5.5 %

NASDAQ HUMA opened at $1.37 on Wednesday. Humacyte, Inc. has a 1-year low of $1.15 and a 1-year high of $9.97. The firm’s fifty day simple moving average is $2.51 and its 200-day simple moving average is $3.98. The company has a market capitalization of $212.51 million, a PE ratio of -1.02 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. As a group, analysts predict that Humacyte, Inc. will post -1.27 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Benchmark reissued a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte presently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.